###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 107 111 <span type="species:ncbi:10090">Mice</span>
Pck1 Gene Silencing in the Liver Improves Glycemia Control, Insulin Sensitivity, and Dyslipidemia in db/db Mice
###end article-title 0
###begin p 1
###xml 43 58 43 58 <email xmlns:xlink="http://www.w3.org/1999/xlink">jperales@ub.edu</email>
Corresponding author: Dr. Jose C. Perales, jperales@ub.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
OBJECTIVE-Cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C; encoded by Pck1) catalyzes the first committed step in gluconeogenesis. Extensive evidence demonstrates a direct correlation between PEPCK-C activity and glycemia control. Therefore, we aimed to evaluate the metabolic impact and their underlying mechanisms of knocking down hepatic PEPCK-C in a type 2 diabetic model.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
RESEARCH DESIGN AND METHODS-PEPCK-C gene targeting was achieved using adenovirus-transduced RNAi. The study assessed several clinical symptoms of diabetes and insulin signaling in peripheral tissues, in addition to changes in gene expression, protein, and metabolites in the liver. Liver bioenergetics was also evaluated.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 409 410 409 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
RESULTS-Treatment resulted in reduced PEPCK-C mRNA and protein. After treatment, improved glycemia and insulinemia, lower triglyceride, and higher total and HDL cholesterol were measured. Unsterified fatty acid accumulation was observed in the liver, in the absence of de novo lipogenesis. Despite hepatic lipidosis, treatment resulted in improved insulin signaling in the liver, muscle, and adipose tissue. O2 consumption measurements in isolated hepatocytes demonstrated unaltered mitochondrial function and a consequent increased cellular energy charge. Key regulatory factors (FOXO1, hepatocyte nuclear factor-4alpha, and peroxisome proliferator-activated receptor-gamma coactivator [PGC]-1alpha) and enzymes (G6Pase) implicated in gluconeogenesis were downregulated after treatment. Finally, the levels of Sirt1, a redox-state sensor that modulates gluconeogenesis through PGC-1alpha, were diminished.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-Our observations indicate that silencing PEPCK-C has direct impact on glycemia control and energy metabolism and provides new insights into the potential significance of the enzyme as a therapeutic target for the treatment of diabetes.
###end p 6
###begin p 7
Published ahead of print at  on 28 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
The liver has a central role in maintaining glucose and energy homeostasis. Postabsorptive metabolism in hepatocytes ensures glucose synthesis via gluconeogenesis and glycogenolysis to maintain blood glucose levels. In diabetic patients, sustained rates of gluconeogenesis independent of nutrient status are responsible for increased hepatic glucose output (HGO) and, therefore, hyperglycemia (1,2).
###end p 9
###begin p 10
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1061 1062 1061 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1063 1064 1063 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1115 1119 1115 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 1276 1277 1276 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 1278 1280 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
###xml 814 819 <span type="species:ncbi:10090">mouse</span>
###xml 1055 1059 <span type="species:ncbi:10090">mice</span>
###xml 1268 1274 <span type="species:ncbi:9606">humans</span>
Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the first committed step in gluconeogenesis. Gene transcription from the cytosolic form of PEPCK (PEPCK-C) is highly regulated by the glucagon/insulin axis. In diabetes, the lack of insulin (type 1 diabetes) or resistance to its action (type 2 diabetes) is responsible for an important upregulation of the enzyme, and this induction correlates with increased rates of gluconeogenesis in liver and kidney (3). Also, PEPCK gene modulation in the liver has resulted in remarkable effects on systemic glucose metabolism in mice. A twofold overexpression of PEPCK-C results in insulin resistance (4), whereas a sevenfold overexpression results in hyperglycemia (5). Moreover, studies by Burgess et al. (6) and She et al. (7,8) using a liver-specific PEPCK-C knockout mouse have shed light on the critical role of PEPCK-C in the integration of energy metabolism through a mechanism that implicates cataplerosis from mitochondria, as highlighted by hypoglycemia and lethality after ablation of PEPCK-C gene in mice (7-9). Furthermore, a polymorphism in the promoter for Pck1 is associated with the development of type 2 diabetes (10), and dysregulation of gluconeogenesis has direct implications for glucose homeostasis in humans (2,11).
###end p 10
###begin p 11
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
Despite all evidence, the validation of this enzyme as a target for liver-specific gene therapy or pharmacological intervention in diabetes has not been extensively investigated to date. Prior studies in streptozotocin-treated mice using RNAi-directed downregulation of PEPCK-C in the liver have shown a direct role for this enzyme in the regulation of glucose homeostasis in the absence of insulin (12). Here, we have focused on evaluating the indirect metabolic impact of knocking down hepatic PEPCK-C in a model of insulin resistance.
###end p 11
###begin p 12
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
We show that partial silencing of hepatic PEPCK-C in db/db mice leads to improved glycemia control directly, through the coordinate inhibition of components of the gluconeogenic pathway in the liver, and indirectly, by improving insulinemia and peripheral sensitivity to the hormone. Our observations indicate that PEPCK-C plays a key role in the control of hepatic energy metabolism and provides a novel therapeutic approach for the treatment of diabetes.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin title 14
Experimental animals and adenovirus.
###end title 14
###begin p 15
###xml 20 22 20 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Male C57BKS.Cg-+Leprdb/+Leprdb (db/db) mice were purchased from Harlan Interfarma, maintained in a constant 12-h light/dark cycle, and fed a standard rodent chow and water ad libitum. At the beginning of the experiment, animals were 6-8 weeks old. All animal protocols were approved by the ethics committee at the University of Barcelona.
###end p 15
###begin p 16
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 99 116 99 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Phothinus pyralis</italic>
Recombinant E1-E3 deficient adenovirus (serotype 5) encoding shRNA against PEPCK-C (Ad-shPck1) and Phothinus pyralis luciferase (Ad-shCT) (used as unspecific control sequence) were generated in the Viral Production Unit of the Center of Animal Biotechnology and Gene Therapy (UPV-CBATEG) (Bellaterra, Spain).
###end p 16
###begin p 17
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 180 184 179 183 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m.</sc>
Adenovirus was administered by tail vein injection of 6.67 x 1010 plaque-forming units (pfu)/kg in 200 mul physiological saline. Fed blood glucose and weight were measured at 8:00 a.m. Surgery was performed under isofluorane anesthesia (Abbot). Tissues were snap-frozen in liquid nitrogen and stored at -80degreesC until analysis. Blood was collected by inferior cava puncture.
###end p 17
###begin title 18
Peripheral insulin sensitivity.
###end title 18
###begin p 19
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Overnight fasted mice were anesthetized, and gastrocnemius muscle, epididymal fat, and liver samples were taken at time 0 and 5 min after a 10-IU/kg insulin bolus was injected via tail vein.
###end p 19
###begin title 20
Glucose and insulin tolerance tests.
###end title 20
###begin p 21
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 229 235 <span type="species:ncbi:9913">bovine</span>
Glucose tolerance was assayed 7 days after treatment in 32-h-fasted mice after a 1-g/kg glucose bolus intraperitoneal injection. Insulin tolerance was determined in mice fed ad libitum, after intraperitoneal injection of 2 IU/kg bovine insulin (Sigma) at day 8 after treatment. Blood glucose was measured at the indicated time points after challenge.
###end p 21
###begin title 22
Glucose production from pyruvate.
###end title 22
###begin p 23
###xml 87 91 <span type="species:ncbi:10090">mice</span>
A 2 g/kg buffered pyruvate (Sigma) bolus was injected intraperitoneally in 32-h-fasted mice on day 7 after adenoviral infection. Glucose levels were measured at indicated time points.
###end p 23
###begin title 24
RNA extraction and quantitative RT-PCR.
###end title 24
###begin p 25
Total RNA was extracted using RNAeasy mini kit (Qiagen). cDNA synthesis from 2 mug RNA was performed using Ready-To-Go You-Prime First Strand Beads (Amersham Biosciences) with random hexamers. mRNA levels of selected genes were quantified using a Low Density Array (Applied Biosystems) in a HT7900 Real-Time RT-PCR system (Applied Biosystems). Gene expression was normalized with beta-2-microglobulin as a housekeeping gene. Data analysis is based on the DeltaDeltaCt method.
###end p 25
###begin title 26
Western blot.
###end title 26
###begin p 27
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 382 384 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
Tissue was homogenized in radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors and centrifuged at 15,000g for 15 min at 4degreesC. Western blots were performed with 20-50 mug tissue extract. Proteins were separated in 8-12% SDS-PAGE and transferred to an Immobilon membrane (Millipore). Nuclear extracts were obtained as described previously (13).
###end p 27
###begin p 28
###xml 188 190 188 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">79</sup>
###xml 287 290 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">172</sup>
###xml 308 311 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 324 327 324 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 755 758 743 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 0 5 <span type="species:ncbi:9940">Sheep</span>
###xml 975 986 <span type="species:ncbi:3704">Horseradish</span>
Sheep anti-PEPCK-C antiserum (a gift from Dr. Granner, Vanderbilt University, Nashville, TN) was used at a 1:20,000 dilution; antibodies against acetyl-CoA carboxylase (ACC) and ACC-P (Ser79) (Upstate) were used at 1:2,000; and antibodies against AMP-dependent kinase (AMPK), AMPK-P (Thr172), AKT, AKT-P (Thr308), AKT-P (Ser473) (Cell Signaling), Sirt1 (Upstate), and sterol regulatory element-binding protein 1c (SREBP-1c; Santa Cruz Biotechnology) were used at 1:1,000. Voltage-dependent anion channel (VDAC) antibody (provided by Dr. Pujol, IDIBELL) was diluted 1:1,000. Fatty acid synthase (FAS) and protein kinase C epsilon (PKCepsilon) antibodies (Santa Cruz Biotechnology) were used at 1:500 dilution. FOXO1 (Santa Cruz Biotechnology), FOXO1-P (Ser256) (Cell Signaling), and peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1 (Cell Signaling) were used at 1:250. All membranes were normalized using monoclonal anti-gamma-tubulin (Sigma) at 1:10,000. Horseradish peroxidase activity linked to secondary antibody was detected with ECL substrate (Pierce) in a Fujifilm LAS 3000 Intelligent Dark Box IV imaging system. Densitometry was performed using Multi Gauge software.
###end p 28
###begin p 29
###xml 176 177 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 242 243 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 371 372 359 360 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
PKCepsilon activity was estimated as the ratio of membrane to cytosol PKCepsilon signal. To separate membrane and cytosolic fractions, liver homogenates were centrifuged at 800g for 10 min, and supernatants were further centrifuged at 100,000g for 45 min. Enrichment was assessed after blotting the membranes with antibodies (1:1,000) against cytosolic (pyruvate kinase [l-PK]; gift from Dr. Bartrons, University of Barcelona) and membrane-associated (epithelial growth factor receptor [EGFR], gift from Dr. Rosa, University of Barcelona) proteins.
###end p 29
###begin title 30
Histology and immunofluorescence.
###end title 30
###begin p 31
###xml 317 319 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
A portion of the third hepatic lobule was fixed for at least 24 h in 4% paraformaldehyde, equilibrated in 30% saccharose, embedded in Tissue-Tek OCT compound (Sakura), and stored at -80degreesC until 7-mum-thick cryosections were obtained. Oil-red lipid staining and PEPCK-C immunostaining were previously described (12).
###end p 31
###begin title 32
Blood and liver biochemical analysis.
###end title 32
###begin p 33
###xml 301 306 <span type="species:ncbi:10090">Mouse</span>
Blood glucose was measured using a Glucocard Memory 2 apparatus (Menarini) by tail clipping. Serum metabolites were measured in the Veterinarian Clinical Biochemistry Service, Veterinary Hospital, Universitat Autonoma de Barcelona (Barcelona, Spain). Serum insulin was determined using Ultrasensitive Mouse Insulin ELISA (Mercodia). HDL cholesterol was quantified using a Reflotron system (Roche Diagnostics).
###end p 33
###begin p 34
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
Hepatic glycogen was measured essentially as previously described (9). Hepatic triglycerides and fatty acid content were quantified using a TAG kit (Sigma) and NEFA kit (Wako), respectively, in 3 mol/l KOH, 65% ethanol extracts, based on the method of Salmon and Flatt for liver saponification. Hepatic short chain acyl-CoAs (acetyl-CoA, malonyl-CoA, propionyl-CoA, and succinyl-CoA) were analyzed by high-performance liquid chromatography (HPLC) as described previously (14) in the Research Support Services from the University of Barcelona. Nucleotides (ATP/ADP/AMP) were determined in neutralized 10% perchloric acid extracts by HPLC.
###end p 34
###begin title 35
High-resolution respirometry.
###end title 35
###begin p 36
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 269 271 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 387 388 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 814 815 802 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
O2 consumption was measured using a high-resolution Oxygraph respirometer (Oroboros, Innsbrook, Austria) in isolated hepatocytes. Briefly, liver was preperfused with calcium-free Hanks' balanced salt solution (HBSS) buffer (Sigma) at 37degreesC before perfusion with Ca2+-containing HBSS and 3.5 mg/ml Liberase Blendzyme (Roche). Hepatocytes were cleared by repeated centrifugation at 50g for 5 min, and viability (>80%) was assessed by trypan blue exclusion. The respiration medium consisted of F-12 Coon's modification supplemented with 20 mmol/l HEPES, 20 mmol/l lactate, 2 mmol/l pyruvate, 2 mmol/l glutamine, and 1 mmol/l octanoate conjugated with 0.5% BSA. Medium was equilibrated with air at 37degreesC and stirred at 750 rpm until a stable signal was obtained for calibration at air saturation. At least 106 hepatocytes per milliliter were used for measurements. The titration protocol, which was completed within 50-60 min, was recorded at 2-s intervals using a computer-driven data acquisition system (Datlab; Oroboros).
###end p 36
###begin title 37
Statistical analysis.
###end title 37
###begin p 38
###xml 138 139 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 148 149 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Results are expressed as the means +/- SE. Statistical analysis was always performed by one-way or two-way ANOVA and two-tailed Student's t test. A P < 0.05 was considered significant.
###end p 38
###begin title 39
RESULTS
###end title 39
###begin title 40
Liver-specific PEPCK-C gene silencing.
###end title 40
###begin p 41
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 322 329 322 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 595 596 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 603 604 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 620 621 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 626 627 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 614 627 610 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic> and <italic>D</italic></xref>
###xml 846 847 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 852 853 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 840 853 836 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic> and <italic>D</italic></xref>
###xml 1044 1045 1040 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1038 1045 1034 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
A previously validated shRNA sequence against PEPCK-C (12) was engineered into an adenovirus vector (Ad-shPck1) and tested for relative silencing efficiency compared with a control sequence (Ad-shCT). Treatment with Ad-shPck1 achieved a 42 and 25% reduction in Pck1 gene expression in fed and fasted livers, respectively (Fig. 1A). Interestingly, the net amount of RNA silenced was similar independent of nutritional status. Densitometric quantification of Western blots confirmed a similar amount of hepatic PEPCK-C protein reduction on treatment (100 +/- 15.1 vs. 46.1 +/- 6.8 relative units; n = 11, P < 0.01) (Fig. 1C and D). Because PEPCK-C is also present in kidney and adipose tissue, we assessed the tissue specificity of silencing. No changes in PEPCK-C protein content were observed either in kidney or epididymal adipose tissue (Fig. 1C and D). Finally, immunohistochemical analysis of PEPCK-C demonstrates a nonhomogeneous reduction of PEPCK-C immunoreactivity that is more evident in pericentral than periportal hepatocytes (Fig. 1B).
###end p 41
###begin title 42
Whole-body glucose homeostasis and insulin sensitivity.
###end title 42
###begin p 43
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 366 367 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 360 367 354 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 487 488 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 481 488 475 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
To investigate the consequences of PEPCK-C silencing on glycemia control, key metabolic parameters were measured. Fed blood glucose was significantly reduced in Ad-shPck1 animals (271 +/- 23 mg/dl) compared with both saline-treated (409 +/- 48 mg/dl) and Ad-shCT-treated (370 +/- 38 mg/dl) groups, although no significant changes were found in fasted animals (Fig. 2A). Interestingly, PEPCK-C silencing and oral metformin treatment demonstrated similar variations in fed glycemia (Fig. 2B).
###end p 43
###begin p 44
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 264 265 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 258 265 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 355 359 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 367 368 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 361 368 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 505 506 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 499 506 487 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 527 531 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 591 592 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 617 618 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 627 628 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 656 657 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 666 667 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 679 683 661 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 810 812 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
Systemic glucose clearance, assessed using a glucose tolerance test, was improved after Ad-shPck1 treatment, as demonstrated by a reduction in the area under the curve of approximately40 and 20% compared with saline-treated and Ad-shCT groups, respectively (Fig. 2C). Also, fed and fasting insulinemia were significantly reduced after treatment with Ad-shPck1 (Fig. 3A). Accordingly, an intraperitoneal insulin tolerance test showed that PEPCK-C-silenced animals have higher sensitivity to insulin (Fig. 3B). Furthermore, Ad-shPck1-treated animals scored significantly lower (2.38 +/- 0.01, n = 14 vs. 2.74 +/- 0.07, P < 0.01, n = 5 and vs. 2.53 +/- 0.01, P < 0.05, n = 14; Ad-shPck1 vs. saline treated and vs. Ad-shCT, respectively) when their degree of insulin resistance was assessed from the QUICKI index (15).
###end p 44
###begin p 45
###xml 207 210 207 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 218 221 218 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 386 393 386 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 514 519 <span type="species:ncbi:10090">mouse</span>
Next, we directly evaluated insulin signaling in vivo measuring insulin-stimulated AKT phosphorylation in liver, muscle, and epididymal adipose tissue (white adipose tissue [WAT]). AKT phosphorylation at Ser473 and Thr308 was enhanced in Ad-shPck1-treated animals after insulin treatment, in marked contrast to reduced signaling by insulin in saline-treated and Ad-shCT-treated groups (Fig. 3C-H). These data demonstrate improved peripheral insulin sensitivity after partial hepatic PEPCK-C knockdown in the db/db mouse model.
###end p 45
###begin title 46
Gluconeogenesis and HGO.
###end title 46
###begin p 47
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 110 111 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 104 111 104 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 206 213 206 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
HGO, determined by the flux from pyruvate to glucose in vivo, was reduced in Ad-shPck1-treated animals (Fig. 4A). Moreover, liver glycogen was significantly reduced in Ad-shPck1-treated animals on fasting (Table 1), consistent with decreased hepatic glucose production capacity
###end p 47
###begin p 48
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G6pc</italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 423 432 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hnf4&#945;</italic>
###xml 494 506 478 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppargc1&#945;</italic>
###xml 581 582 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 575 582 551 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 653 654 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 659 660 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 647 660 619 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic> and <italic>D</italic></xref>
###xml 778 781 746 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 809 813 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 837 838 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 843 844 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 831 844 799 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>E</italic> and <italic>F</italic></xref>
###xml 1031 1035 999 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G6pc</italic>
###xml 1040 1045 1008 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1.</italic>
Glucose-6-phosphatase catalyzes the last step in the gluconeogenic and glycogenolysis pathways, and is, therefore, responsible for regulating HGO. The mRNA of this enzyme (encoded by G6pc) was significantly reduced at levels comparable with those observed for PEPCK-C (encoded by Pck1). Glucose-6-phosphatase and PEPCK-C are regulated by transcription factors like hepatocyte nuclear factor-4alpha (HNF-4alpha) (encoded by Hnf4alpha) and FOXO1, which are co-activated by PGC-1alpha (encoded by Ppargc1alpha). PGC-1alpha mRNA was slightly reduced in PEPCK-C-silenced animals (Fig. 4B), although PGC-1alpha protein in nuclear extracts was constant (Fig. 4C and D). HNF-4alpha is downregulated, albeit nonsignificantly, in treated animals. In addition, FOXO1 phosphorylation at Ser256 increased in liver of Ad-shPck1-treated animals (Fig. 4E and F). These data suggest that insulin signaling through AKT-dependent FOXO1 phosphorylation contributes to the observed reduction in steady-state mRNA levels for gluconeogenic genes such as G6pc and Pck1.
###end p 48
###begin title 49
Lipid homeostasis.
###end title 49
###begin p 50
###xml 453 460 450 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
To investigate the effects of liver-specific PEPCK-C knockdown on lipid metabolism, several blood and liver parameters were analyzed. Serum triglycerides were pronouncedly reduced both in fed and fasted animals after PEPCK-C silencing in the liver, accompanied by decreased serum free fatty acids (FFAs) and increased beta-hydroxybutyrate. Furthermore, a net increase in total serum cholesterol with a concomitant increase in HDL cholesterol was found (Table 1).
###end p 50
###begin p 51
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 302 309 302 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 468 475 468 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 604 605 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 598 605 582 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 743 744 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 749 750 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 737 750 721 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic> and <italic>E</italic></xref>
###xml 847 850 831 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gck</italic>
###xml 853 854 837 838 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 876 880 860 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mod1</italic>
###xml 930 931 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 924 931 908 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 932 933 916 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1000 1001 984 985 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 1062 1063 1046 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1056 1063 1040 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1064 1065 1048 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1136 1140 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 1149 1153 <span type="species:ncbi:10090">mice</span>
Lipid accumulation in the liver is a characteristic of the diabetes phenotype in db/db mice. Oil-red staining demonstrated both micro- and macrovesicular lipid droplets in Ad-shCT-treated livers, which are more profuse in Ad-shPck1 group, especially in periportal compared with perivenous hepatocytes (Fig. 5A). Consistently, we observed a moderate increase in hepatic triacylglycerol (TAG) and a 3.5-fold increase in liver fatty acid content after PEPCK-C silencing (Fig. 5B). Meanwhile, the level of FAS mRNA was unaltered, whereas SREBP1-c and liver X receptor-alpha decreased approximately25% (Fig. 5C). Correspondingly, the precursor (p125) and active form (p68) of SREBP1-c were reduced, whereas FAS protein content was unchanged (Fig. 5D and E). Moreover, mRNA and protein levels from glycolytic and lipogenic enzymes, such as glucokinase (Gck), l-PK, or malic enzyme (Mod1), were unaltered or significantly reduced (Fig. 5C-E). ChREBP, which plays an important role in regulating glycolytic (l-PK) and lipogenic (ACC and FAS) genes, was unaltered (Fig. 5C-E), which supports the absence of de novo lipogenesis in livers of Ad-shPck1-treated mice.
###end p 51
###begin p 52
###xml 199 201 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 279 286 276 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 448 449 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 442 449 439 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>F</italic></xref>
###xml 527 532 524 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
Malonyl-CoA is an important contributor to the opposing regulation of fatty acid beta-oxidation and fatty acid synthesis through its dual function as allosteric inhibitor of CPT-1 and FAS substrate (16). Although a significant increase of malonyl-CoA content in liver was found (Table 2), ACC, the enzyme responsible for its synthesis, was not stimulated because the ratio of ACC-P to ACC was unchanged in the liver of PEPCK-C-silenced mice (Fig. 5F). These data further support the view that PEPCK-C silencing in the liver of db/db mice does not induce net de novo lipogenesis.
###end p 52
###begin p 53
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 40 53 40 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic> and <italic>B</italic></xref>
###xml 139 145 139 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 234 236 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 315 320 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 335 336 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 341 342 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 329 342 317 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>G</italic> and <italic>H</italic></xref>
Interestingly, despite liver lipidosis (Fig. 5A and B), hepatic and peripheral insulin signaling was improved in PEPCK-C-silenced animals (Fig. 3). PKCepsilon plays a critical role in mediating fat-induced hepatic insulin resistance (17). No activation of PKCepsilon was observed after partial PEPCK-C knockdown in db/db livers (Fig. 5G and H), suggesting that lipid accumulation is dissociated from insulin resistance induction in our model.
###end p 53
###begin title 54
Modulation of energy metabolism.
###end title 54
###begin p 55
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 403 404 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 397 404 391 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 563 564 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 557 564 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 647 654 634 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 720 721 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 714 721 701 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 810 817 794 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
Because impairment of the tricarboxylic acid (TCA) cycle and mitochondrial function are hallmarks of liver-specific PEPCK-C knockout mice (6,8,9), we evaluated several parameters of mitochondrial function, including beta-oxidation. The rate-limiting step in beta-oxidation is the transport of acyl-CoA into the mitochondria catalyzed by the CPT-1 shuttle, whose mRNA content was slightly reduced (Fig. 6B). Consistently, the mRNA for PGC-1alpha, a key player in the regulation of both beta-oxidation and gluconeogenic pathways, was lowered after treatment (Fig. 4B). In contrast, a slight increase in serum ketones in both fed and fasted animals (Table 1), together with unchanged levels of HMG-CoA synthase mRNA (Fig. 6B) and a significant increase in propionyl-CoA, an odd chain beta-oxidation intermediate (Table 2), suggests that beta-oxidation was not markedly affected.
###end p 55
###begin p 56
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 282 289 282 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 365 372 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 787 794 787 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 990 991 990 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 984 991 984 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 1162 1166 1162 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1184 1185 1184 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1178 1185 1178 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 1292 1296 1292 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ucp2</italic>
###xml 1380 1381 1380 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1374 1381 1374 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
The mitochondrial respiration rate, determined in freshly isolated hepatocytes in the presence of octanoate, was unaffected by treatment with Ad-shPck1. Moreover, the maximum mitochondrial respiration capacity (uncoupler carbonyl cyanide p-trifluoromethoxyphenyl-hydrazone [FCCP]) (Fig. 6A) and the content of the inner mitochondrial membrane ADP transporter VDAC (Fig. 6C), a marker of the amount of respiratory chains and hence mitochondrial content, were unchanged, suggesting that partial PEPCK-C knockdown does not impair the TCA cycle and does not negatively affect mitochondrial biogenesis or limit mitochondrial oxidative capacity in excess of medium-chain fatty acid substrate. Consistently, no accumulation of TCA intermediates, like acetyl-CoA and succinyl-CoA, was observed (Table 2). Additionally, the expression profile of cytosolic (decreased) and mitochondrial (unaltered) superoxide dismutases (SODs) is compatible with increased peroxisomal oxidation activity (18) (Fig. 6D). The ratios estimated from respirometry data (respiratory control ratio [RCR], uncoupling control ratio [UCR], and phosphorylation RCR [RCRP]) were unaltered after Ad-shPck1 treatment (Fig. 6A). In agreement with UCR index, the level of expression from the gene encoding the uncoupling protein two (Ucp2) was unchanged, suggesting that mitochondrial respiration was not uncoupled (Fig. 6B).
###end p 56
###begin p 57
###xml 498 505 495 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 559 561 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 702 703 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 696 703 693 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>E</italic></xref>
###xml 778 779 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 772 779 769 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
It is widely accepted that gluconeogenesis is dependent on fatty acid oxidation as an energy source. An imbalance between these two pathways would, theoretically, alter cellular energy charge (CEC), unless a corresponding energy producing or consuming pathway compensates for such disequilibrium. Our data show an apparent reduction in gluconeogenesis while beta-oxidation is maintained. Consistently, CEC was greatly increased because of a 25% reduction of AMP and a 50% increment in ATP content (Table 2). As a result, the master-switch energy sensor AMPK (19), which is activated by decreasing energy charge, was not stimulated, as determined by the ratio of phosphorylated versus total AMPK (Fig. 6E), and ACC, a target for AMPK, was not inhibited by phosphorylation (Fig. 5D).
###end p 57
###begin p 58
###xml 28 30 28 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 471 472 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 478 479 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 499 500 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 571 572 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 565 572 545 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>F</italic></xref>
###xml 573 574 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
The work of Rodgers et al. (20) sheds some light on the regulation of gluconeogenesis in response to nutrients and changes in redox potential mediated by Sirt1, a NAD+-dependent deacetylase involved in PGC-1alpha activation. Therefore, we evaluated the levels of Sirt1 to investigate whether the pathway could be responsible for the coordinated reduction in gluconeogenic enzymes and regulatory factors. A reduction of approximately50% (100 +/- 9.16 vs. 47.03 +/- 10.19; n = 7; P < 0.001; Student's t test) in the levels of Sirt1 protein in the liver was observed (Fig. 6F-G).
###end p 58
###begin title 59
DISCUSSION
###end title 59
###begin p 60
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
The natural tropism of adenovirus for the liver was used to obtain efficient, organ-specific delivery of a shRNA-producing expression vector against PEPCK-C. Infection of db/db mice with adenovirus-directed shRNA allowed inhibition of PEPCK-C specifically in the liver, with unaltered levels in kidney and WAT, where PEPCK-C has important roles in gluconeogenesis from glutamine and glyceroneogenesis, respectively (3).
###end p 60
###begin p 61
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 180 187 180 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 346 348 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
Inmunostaining experiments show a PEPCK-C gradient across the porto-central axis of the liver acinus (21). Silencing efficiency was higher in the perivenous portion of the acinus (Fig. 1C), where PEPCK-C levels are lower. Although similar silencing pattern and efficiency (approximately50%) was obtained in our previous study on type 1 diabetes (12) using a hydrodynamic gene transfer technique, the present report demonstrates that the use of adenovirus can result in an absolute higher silencing efficiency (Supplementary Fig. 1, which is detailed in an online appendix [available at ]) and longer lasting effects (up to 2 weeks), which allowed us to evaluate the metabolic impact and underlying mechanisms of knocking down hepatic PEPCK-C in a type 2 diabetes model.
###end p 61
###begin p 62
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with reduced PEPCK-C liver content showed a clear improvement in glucose tolerance and fed glycemia, comparable with the results of oral metformin treatment. However, fasting glucose was unchanged, even though HGO from pyruvate was clearly reduced. Compensatory HGO from glycogenolysis, as supported by reduced hepatic glycogen content in fasting and even in fed animals when silencing reached 90% (Supplementary Fig. 1), could be responsible for unchanged fasting glycemia. Accordingly, fasting glycemia was significantly reduced in treated animals when PEPCK-C was 90% silenced (Supplementary Fig. 1).
###end p 62
###begin p 63
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 769 772 769 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 796 799 796 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1154 1156 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1333 1335 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 344 349 <span type="species:ncbi:10090">mouse</span>
Improved glucose tolerance and insulinemia suggest increased peripheral insulin sensitivity. Lower insulin levels could be secondary to reduced glycemia; however, phloridzin treatment, which inhibits intestinal glucose uptake and renal reabsorption, has been shown to reduce glycemia with no effects on insulin sensitivity in a type 2 diabetes mouse model (22). Moreover, an ameliorated intraperitoneal insulin tolerance test (IPITT) and higher insulin-stimulated AKT phosphorylation in muscle and adipose tissue strongly support the hypothesis of an insulin-sensitizing effect. In adipose tissue, AKT phosphorylation at Thr 308 was unchanged by either treatment. However, it has been shown that insulin-stimulated glucose uptake is independent of signaling through Thr308 and closely matches Ser473 AKT-P levels (23). The QUICKI index was also suggestive of an overall reduction in insulin resistance. In addition, hepatic PEPCK-C silencing improves clinical symptoms of type 2 diabetes, such as polydipsia, polyuria, and glycosuria, as revealed by metabolic cage studies (data not shown). Cross talking between liver and brain through the vagal nerve (24) could be responsible for a coordinated metabolic regulation in peripheral tissues in response to hepatic energy metabolism modulation, affecting systemic insulin sensitivity (25).
###end p 63
###begin p 64
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 541 543 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Interestingly, despite hepatic lipid accumulation, AKT phosphorylation was also evident in the liver of PEPCK-C-silenced mice. Hepatic lipidosis is commonly associated with the induction of insulin resistance through incompletely understood mechanisms. Recent reports have demonstrated that lipid-induced hepatic insulin resistance is not mediated by fatty acid or TAG accumulation per se (26,27). Instead, diacylglycerol induces insulin resistance via activation of PKCepsilon translocation to the vicinity of insulin receptor substrate-2 (17). In agreement with AKT phosphorylation data, we have observed that PKCepsilon is not modulated by PEPCK-C silencing, reinforcing the current view that lipid accumulation is not necessarily linked to insulin resistance in the liver.
###end p 64
###begin p 65
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 1309 1311 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 1459 1460 1459 1460 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1904 1906 1904 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
Dislipidemia is associated with obesity and insulin resistance in type 2 diabetes (28). PEPCK-C silencing resulted in reduced plasma TAG, together with an important elevation of hepatic lipids, mainly nonsterified fatty acids. An important but not sufficiently appreciated role for PEPCK-C in the liver is glyceroneogenesis: the provision of glycerol-3-phosphate to sustain fatty acid re-esterification for triglyceride synthesis (29,30). Therefore, PEPCK-C silencing could induce a significant reduction in fatty acid re-esterification activity. How to reconcile a concomitant increase in liver TAG and a reduction of TAG in plasma is not apparent. However, elevated fatty acids in the liver could be originated from excess import, reduced oxidation, and/or increased de novo synthesis. Results presented above support that PEPCK-C-silenced livers maintain mitochondrial function. Long- and medium-chain fatty acid oxidation are highly regulated through PEPCK-C import into the mitochondria at the level of CPT-1. Reduced CPT-1 mRNA levels in PEPCK-C-silenced animals, together with increased malonyl-CoA content, a potent allosteric inhibitor of CPT-1, provide indirect evidence for a slight inhibition of fatty acid oxidation. However, this allosteric inhibition can be overridden by fatty acid abundance (31,32). Moreover, it is clear from our data that no blockade at the level of mitochondria is responsible for the accumulation of fatty acids because O2 consumption in the presence of octanoate, which is imported into mitochondria independently of CPT-1, is unaffected in PEPCK-C-silenced hepatocytes. Also, increased plasma ketones and cellular propionyl-CoA is suggestive of maintained mitochondrial and increased peroxisomal oxidation. Actually, after a low-dose ciprofibrate-mediated peroxisome proliferation, SOD expression is modulated with a similar pattern to that observed in our model (18).
###end p 65
###begin p 66
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 539 541 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 542 544 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 748 750 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
The contribution of de novo lipogenesis to the accumulation of TAG and fatty acids seen in livers of Ad-shPck1 treated mice can also be discarded. Key regulatory factors involved in lipogenesis were either maintained (ChREBP) or reduced (SREBP1c and LXR-alpha). Lipogenic enzymes regulated by these factors (ACC and FAS) were unaltered, suggesting a main contribution of ChREBP in gene expression regulation of these targets. Whether liver glucokinase (GK) might be a target gene for SREBP1c-mediated induction has remained controversial (33,34). Our data revealed no alteration on GK mRNA or protein levels, suggesting that the LXR-alpha/SREBP1c axis is not directly regulating GK in our model, in agreement with results obtained by Mitro et al. (35) using a LXR-alpha agonist.
###end p 66
###begin p 67
Fatty acid uptake and activation could instead contribute to the liver fat accumulation and to decreased serum TAG and FFA. FFA import and activation into the liver is an ATP-consuming step that could be sustained by the increased CEC. Therefore, lipid accumulation in the liver might be multifactorial, involving increased uptake from peripheral fat stores and reduced triglyceride synthesis, VLDL assembly, and export.
###end p 67
###begin p 68
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 818 819 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 820 821 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 822 823 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 824 826 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 941 943 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1742 1744 1736 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1879 1881 1873 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 2061 2071 2055 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar-&#945;</italic>
###xml 2160 2170 2150 2156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar-&#945;</italic>
###xml 2172 2174 2158 2160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 1396 1400 <span type="species:ncbi:10090">mice</span>
###xml 1736 1740 <span type="species:ncbi:10090">mice</span>
###xml 2081 2086 <span type="species:ncbi:10090">mouse</span>
###xml 2219 2223 <span type="species:ncbi:10090">mice</span>
Liver-specific knockout animals are euglycemic and able to bypass the complete absence of PEPCK-C activity in their livers with extrahepatic gluconeogenesis (8). Burgess et al. (36) have presented data demonstrating a weak flux control coefficient for gluconeogenesis in partial PEPCK-C knockout mice, suggesting that other factors like TCA cycle flux could contribute to gluconeogenic flux independent of PEPCK protein content. Because PEPCK-C is not only required for gluconeogenesis and glyceroneogenesis but also for cataplerosis (i.e., the removal of citric acid cycle anions), the failure of this process would result in an impairment in the TCA cycle and mitochondrial function in the liver, leading to decreased beta-oxidation and oxygen consumption, together with a complete derangement in energy metabolism (6,8,9,36). Data presented in this manuscript, together with our previous study in streptozotocin-induced diabetic animals (12), demonstrate that a 50% reduction of PEPCK expression results in reduced HGO and glycemia. In addition, mitochondrial respiration and CPT-1-independent beta-oxidation of fatty acids is not affected, suggesting that TCA cycle flux was sustained as long as intermediates (acetyl-CoA and succinyl-CoA) were not accumulated and ketones were overproduced. The discrepancy among the various studies might be related to one of three factors. First, knockout mice have a complete ablation of the PEPCK-C gene in the liver, in contrast to the partial reduction in the enzyme described in this study. In fact, 90% reduction in PEPCK-C protein levels in the liver, obtained with higher adenoviral dosage (Supplementary Fig. 1), reproduce the blockade on mitochondrial function observed in the knockout mice (36). Second, adaptation to a lack of PEPCK-C in knockout animals as a consequence of deletion of the gene very early during development (37) may induce a compensatory increase in gluconeogenesis in tissues other than the liver. In this regard, a recent study points to a disparity between results obtained from a liver Ppar-alpha knockout mouse and a short-term knockdown model using chemically modified siRNA against Ppar-alpha (38). Third, studies on liver-specific knockout mice were directed toward understanding the physiological role of PEPCK-C in the liver. To our knowledge, liver PEPCK-C knockout animals have not been previously studied in relevant models of diabetes, such as the one presented in this study.
###end p 68
###begin p 69
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 423 424 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 575 577 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 712 714 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 715 717 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 891 893 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1210 1212 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1603 1608 1591 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1645 1647 1633 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 1609 1613 <span type="species:ncbi:10090">mice</span>
The coordinated regulation of several key players in energy homeostasis in the livers of Ad-shPck1-treated animals is an intriguing observation. We have identified Sirt1 as a probable mediator in the response of the cell to a partial reduction in PEPCK-C content. A nutrient signaling response mediated by pyruvate induces Sirt1 protein in liver during fasting, where it interacts with and deacetylates PGC-1alpha in an NAD+-dependent manner, increasing PGC-1alpha ability to coactivate HNF-4alpha and, therefore, upregulate gluconeogenic genes, but not mitochondrial genes (20). In addition, Sirt1-mediated deacetylation of FOXO1 has been shown to promote its transcriptional activity over gluconeogenic genes (39,40), suggesting an integrated regulation by insulin and Sirt1 over gluconeogenesis in treated animals. Moreover, Sirt1 transcription is inhibited by a NADH-mediated mechanism (41). In this context, Sirt1 seems to function as a nutrient sensor by decoding fluctuations in cellular NADH levels. Therefore, our observation of a substantial reduction of Sirt1 identifies this nutrient sensor as a potential mediator of the coordinated downregulation of gluconeogenesis. Recent data from Sun et al. (42) have shown that oral administration of resveratrol, an activator of Sirt1, improves glucose homeostasis and insulin sensitivity mainly though its action on muscle. However, the potential for Sirt1 as a therapeutic target for diabetes in the liver is curtailed by its role in gluconeogenesis, as recently suggested by reduced HGO and improved glucose homeostasis and insulin sensitivity in db/db mice after hepatic Sirt1 silencing (43).
###end p 69
###begin p 70
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 936 941 <span type="species:ncbi:9606">human</span>
All in all, we present evidence to sustain that partial silencing of liver PEPCK-C in db/db mice leads to improved control of glycemia, insulinemia, and peripheral sensitivity to the hormone through its coordinate inhibition of key players responsible for the activation of liver gluconeogenesis, in the absence of a blockade at the level of mitochondria. In addition, we show that this model represents a departure from the view, recently challenged, that steatosis leads to insulin resistance. Finally, our observations join the growing body of evidence that indicates that PEPCK-C plays a key role in the control of hepatic energy metabolism in type 2 diabetes animals, validating liver PEPCK-C as a target for pharmaceutical intervention. Nonetheless, in view of the known discrepancy between the large contribution of gluconeogenesis to hepatic glucose production in small rodent models as compared to large animals (i.e., canine, human) the suitability of the approach should be further tested in a larger animal model.
###end p 70
###begin title 71
Supplementary Material
###end title 71
###begin title 72
Online-Only Appendix
###end title 72
###begin p 73
A.G.G.V. has received a fellowship from IDIBELL. A.V.A. has received a fellowship from DURSI (Generalitat de Catalunya). A.M. has received a fellowship from F.P.I. (Ministerio de Educacion y Ciencia). This study was supported by a grant from the Ministerio de Educacion y Ciencia (BFU2006-02802).
###end p 73
###begin p 74
We thank the Research Support Services from the Biology Unit of Bellvitge (University of Barcelona) for their technical assistance, Dr. Anna Serafin for her skillful assistance with histopathology, and Dr. Maria Molas for her invaluable assistance reviewing the manuscript.
###end p 74
###begin title 75
REFERENCES
###end title 75
###begin p 76
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 283 284 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 437 441 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 536 537 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 594 595 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 835 840 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 999 1000 993 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1212 1213 1202 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1254 1255 1244 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1271 1272 1261 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1288 1289 1278 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1310 1311 1300 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1401 1402 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1421 1422 1378 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
Adenovirus-mediated shRNA knocks down PEPCK-C specifically in the liver. A dose of 6.67 x 1010 pfu/kg control (Ad-shCT) and PEPCK-C-directed shRNA (Ad-shPck1) adenovirus was injected in male, 6- to 8-week-old db/db mice. A: PEPCK-C expression analyzed by quantitative RT-PCR in fed (n = 11) or overnight-fasted (n = 5) animals 14 days after treatment. beta-2-microglobulin was used as housekeeping gene. Data are represented as relative Pck1 gene expression compared with control-fed animals (Ad-shCT). Data are means +/- SE. Student's t test was used to discriminate statistical significance. B: PEPCK-C immunohistochemistry was performed in 7-mum cryosections obtained from livers treated with either control or PEPCK-C-targeted shRNA. Confocal microscopy was used to determine signal distribution throughout the liver acinus. x100 (right) and x400 image magnification blow up from periportal (PP) and perivenous (PV) zones are shown. Pictures are representative of three independent experiments. C: PEPCK-C immunodetection in total protein extracts from liver, kidney, and epididymal WAT. gamma-Tubulin was used to normalize protein loading. Representative blots from three independent experiments are shown. D: Densitometric quantification of liver (n = 11), kidney (n = 4), and WAT (n = 4) blots shown in C. blacksquare, square, filled, Ad-shCT; square, Ad-shPck1 group. Data are means +/- SE; **P < 0.01, Student's t test. (Please see  for a high-quality digital representation of this figure.)
###end p 76
###begin p 77
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 192 193 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 256 257 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 303 307 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 309 310 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 445 446 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 465 466 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 473 474 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 565 566 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 585 586 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 606 610 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 612 613 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 768 769 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 865 867 809 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 873 875 817 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1162 1163 1104 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1176 1180 1118 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1198 1200 1140 1142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 1200 1201 1142 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1231 1232 1173 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1239 1240 1181 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1373 1400 1315 1342 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 1463 1464 1405 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1480 1481 1422 1423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1498 1501 1440 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck</italic>
###xml 1503 1504 1445 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1520 1521 1462 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1552 1554 1494 1496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 1554 1555 1496 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1568 1571 1510 1513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">###</sup>
###xml 1571 1572 1513 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1609 1610 1551 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1781 1785 1723 1727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1810 1811 1740 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1847 1848 1772 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 1352 1356 <span type="species:ncbi:10090">mice</span>
Knocking down hepatic PEPCK-C in diabetic db/db mice leads to improved glucose homeostasis. A: Fed glycemia (blacksquare, square, filled) was assessed 14 days after treatment with saline (CT; n = 5) with adenovirus expressing a nonspecific shRNA (Ad-shCT; n = 19) or with a PEPCK-C specific shRNA (Ad-shPck1; n = 19). Fasting glycemia was measured after a 32-h fast on day 7 after infection (square) in the same animals. Data are means +/- SE; *P < 0.05, Student's t test. B: Fed glycemia relative to glycemia before treatment. Fed glycemia was scored in CT group (n = 5; o), Ad-shCT (n = 19; *), and Ad-shPck1 (n = 19; black triangle) before treatment and over the duration of the experiment. An additional experimental group was treated orally with metformin (MET) (n = 5; triangle up). Metformin was added to drinking water to achieve a daily dose of 400 mg . kg-1 . day-1 in view of the daily water consumption. Average daily water consumption was calculated every day for 1 week before initialization of experiment. Water consumption and metformin dosage was recalculated twice a week and corrected, if necessary, to adjust dosage. Data are means +/- SE; **P < 0.01 Ad-shPck1 vs. Ad-shCT; and ##P < 0.01 MET vs. CT, Student's t test. C: Seven days after adenoviral infection, an intraperitoneal glucose tolerance test was performed in 32-h-fasted mice as described in research design and methods, and glucose was measured at the indicated time points in CT (n = 5), Ad-shCT (n = 13), and Ad-shPck (n = 12) groups. *P < 0.05 Ad-shPck1 vs. Ad-shCT; ##P < 0.01; and ###P < 0.001 Ad-shPck1 vs. CT, Student's t test. A two-way ANOVA did not detect significant differences between the CT and Ad-shCT groups but demonstrated statistically significant changes when comparing the Ad-shPck1 versus CT (double daggerP < 0.001) and versus Ad-shCT (daggerP < 0.05) treatment groups. Data are means +/- SE.
###end p 77
###begin p 78
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 177 178 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 380 381 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 546 547 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 565 566 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 577 581 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 599 600 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 631 632 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 653 657 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 663 664 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 690 694 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 707 708 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 743 744 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 749 750 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 761 762 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 767 768 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 798 799 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 804 805 758 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 936 963 890 917 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 1010 1013 964 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 1021 1024 975 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 1100 1101 1054 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1102 1103 1056 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1222 1223 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1224 1225 1178 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1333 1337 1241 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1482 1483 1388 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1497 1498 1403 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1517 1518 1423 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
Improved insulin sensitivity in hepatic PEPCK-C-silenced animals. A: Plasma insulin levels was assessed in fed mice 14 days after infection (Ad-shCT, n = 5; Ad-shPck1, n = 4; **P < 0.01, Student's t test) or in 32-h-fasted mice 7 days after infection (Ad-shCT, n = 13; Ad-shPck, n = 12; *P < 0.05, Student's t test). blacksquare, square, filled, Ad-shCT; square, Ad-shPck1 group. B: For IPITT, a 2-IU/kg insulin bolus was injected into awake fed mice. Blood glucose levels were determined at the indicated time points after insulin bolus (CT, o, n = 5; Ad-shCT, *, n = 8; Ad-shPck1, black triangle, n = 9). Data are means +/- SE, *P < 0.05 (CT vs. Ad-shPck1) and P = 0.09 (Ad-shCT vs. Ad-shPck1), Student's t test. Insulin signaling in liver (C and F), muscle (D and G), and epididymal fat depots (E and H) was assessed in overnight fasted mice 1 week after infection by means of an intravenous insulin bolus (10 IU/kg) as described in research design and methods. The level of AKT phosphorylation (at both Ser473 and Thr308 residues) and the total AKT protein content were detected by Western blot (C-E). Representative blots of two independent experiments are shown. Additionally, bands were quantified by densitometry (F-H). 50% shaded block, saline-injected animals (CT); blacksquare, square, filled, Ad-shCT group; square, Ad-shPck1 group. Bars represent the AKT-P-to-AKT ratio related to control (CT) group in the basal state. Data are means +/- SE of 4-6 animals per group. *P < 0.05 and **P < 0.01, Student's t test.
###end p 78
###begin p 79
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 227 254 227 254 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 482 483 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 494 498 492 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 500 501 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 524 525 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 534 535 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 598 602 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G6pc</italic>
###xml 604 614 589 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hnf-4&#945;</italic>
###xml 620 627 601 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppargc1</italic>
###xml 685 686 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 728 734 679 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shPck1</italic>
###xml 736 737 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1107 1108 1042 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1181 1182 1116 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1201 1202 1136 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1209 1210 1144 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1363 1364 1294 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1444 1445 1371 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1578 1579 1495 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1585 1586 1502 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1629 1632 1546 1549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 1805 1806 1722 1723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1861 1862 1778 1779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1930 1933 1847 1850 <sup xmlns:xlink="http://www.w3.org/1999/xlink">256</sup>
###xml 2018 2022 1904 1908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 2030 2031 1916 1917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2039 2040 1925 1926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2059 2060 1945 1946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1301 1305 <span type="species:ncbi:10090">mice</span>
###xml 1710 1714 <span type="species:ncbi:10090">mice</span>
Coordinated downregulation of gluconeogenic genes and decreased hepatic glucose production capacity after hepatic PEPCK-C silencing. A: HGO was evaluated in vivo by assaying the glucose production from pyruvate as described in research design and methods. Hepatic PEPCK-C-silenced group reflected a significant reduction in glucose production capacity after a pyruvate bolus injection. Two-way ANOVA was used to discriminate treatment efficiency. Data are means +/- SE. Ad-shCT, o, n = 9; Ad-shPck1, n = 9, black triangle; *P < 0.05. B: Expression of significant genes involved in gluconeogenesis (G6pc, Hnf-4alpha, and Ppargc1alpha) was examined 2 weeks after treatment with Ad-shCT (n = 10; blacksquare, square, filled) or Ad-shPck1 (n = 11; square) in fed animals. Gene expression was quantified using quantitative RT-PCR in an Applied Biosystems 7900HT Micro Fluidic Card. Data analysis was performed using the DeltaDeltaCt method and beta-2-microglobulin as housekeeping gene. Each value represents the mean relative amount of mRNA with respect to that in the control experimental treatment. Student's t test was used to determine statistical differences between treatments. *P < 0.05, Student's t test. C: Western blot immunodetection of PCG-1alpha in hepatic nuclear extracts obtained from fed mice 14 days after treatment. Representative blots are shown. D: Densitomentric quantification of PGC-1alpha protein content in blots shown in C are represented as PGC-1alpha content relative to gamma-tubulin, which was used to normalize protein charge. Data are means +/- SE, n = 6. E: Phosphorylation level of FOXO1 at the Ser256 residue was analyzed by Western blot in total homogenates of livers from fed mice 14 days after treatment. Total FOXO1 content was used to normalize phosphorylation level. F: Densitometric quantification of blots represented in E. Phosphorylation level is represented as FOXO1-to-phospho-FOXO1 Ser256 ratio relative to control group. blacksquare, square, filled, Ad-shCT; square, Ad-shPck1 group. n = 10, *P < 0.05, Student's t test.
###end p 79
###begin p 80
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 215 226 214 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 428 429 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 542 543 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 576 580 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 590 591 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 633 634 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 645 646 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 655 656 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 730 734 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fasn</italic>
###xml 736 742 702 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">srebf1</italic>
###xml 744 750 710 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">chrebp</italic>
###xml 752 756 718 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mod1</italic>
###xml 758 761 724 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gck</italic>
###xml 767 776 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lxr-&#945;</italic>
###xml 864 865 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 909 913 845 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 915 916 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1254 1255 1174 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1266 1267 1186 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1286 1287 1206 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1294 1295 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1541 1542 1461 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1597 1598 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1603 1604 1523 1524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1629 1630 1547 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1640 1641 1558 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1652 1653 1570 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1672 1673 1590 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1749 1750 1636 1637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1834 1836 1721 1723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">79</sup>
###xml 1874 1878 1761 1765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1996 1997 1879 1880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2067 2094 1950 1977 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 2338 2339 2214 2215 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 2386 2387 2262 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 2436 2437 2312 2313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2559 2560 2427 2428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2617 2621 2454 2458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Effect of hepatic PEPCK-C partial silencing on hepatic lipid homeostasis. A: Livers from fed mice 14 days after treatment were fixed in 4% paraformaldehide, and oil-red staining was performed in 7-mum cryosections. Right panel shows a x100 magnification liver section. A view of periportal (PP) and perivenous (PV) zones are shown with a x200 magnification. Representative pictures from three independent experiments are shown. B: Triglyceride and fatty acid content in fed livers from unspecific shRNA (Ad-shCT; blacksquare, square, filled; n = 14) or PEPCK-C-targeted (Ad-shPck1; square; n = 16) treatment. Data are means +/- SE; *P < 0.05, **P < 0.01. C: Expression of significant genes involved in glycolysis and lipogenesis (fasn, srebf1, chrebp, mod1, gck, and lxr-alpha) was examined. Livers were obtained in fed state 14 days after infection with Ad-shCT (n = 10; blacksquare, square, filled) or Ad-shPck1 (n = 11; square). Gene expression was quantified by quantitative RT-PCR using Applied Biosystems 7900HT Micro Fluidic Card, and data were analyzed using the DeltaDeltaCt method and beta-2-microglobulin as housekeeping gene. Each value represents the mean relative amount of mRNA with respect to that in the control experimental treatment. *P < 0.05, **P < 0.01, Student's t test. D: Protein levels of glycolytic and lipogenic enzymes and transcription factors in livers from fed animals 14 days after treatment were analyzed by Western blot from total liver extracts. Blots are representative of three independent experiments. E: Densitometric quantification of blots represented in D and F. Data are means +/- SE, n = 5-19; *P < 0.05, **P < 0.01, Student's t test. blacksquare, square, filled, Ad-shCT group; square, Ad-shPck1 group. F: Western blot analysis of ACC protein content and phosphorylation levels (ACC-P Ser79) in fed livers from Ad-shCT and Ad-shPck1 groups. Blots were normalized with gamma-tubulin. Representative blots from three independent experiments are shown. G: Liver cytosolic and membrane fraction were isolated as described in research design and methods. Membrane and cytosol fractions (50 mug) were loaded in a 10% SDS-PAGE. PKCepsilon protein content in each fraction was detected by Western blot. Cellular fraction enrichment was assessed with immunodetection of membrane (EGFR) and cytosolic (l-PK) proteins. Representative blots are shown. H: Densitometric quantification of blots shown in G demonstrates unaltered membrane translocation from cytosol of PKCepsilon after PEPCK-C silencing. Data are means +/- SE, n = 6. blacksquare, square, filled, Ad-shCT; square, Ad-shPck1 group. (Please see  for a high-quality digital representation of this figure.)
###end p 80
###begin p 81
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 211 215 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 278 305 247 274 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 701 704 667 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink">COX</sub>
###xml 773 781 738 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N,N,N&#8242;,N</italic>
###xml 902 907 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 930 932 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 1517 1518 1480 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1525 1537 1488 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#167;</sup>
###xml 1537 1538 1489 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1557 1558 1509 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1565 1566 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1636 1640 1588 1592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ucp2</italic>
###xml 1642 1646 1594 1598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cpt1</italic>
###xml 1652 1657 1604 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hmgc2</italic>
###xml 1688 1689 1640 1641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1733 1737 1659 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 1739 1740 1665 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2302 2303 2212 2213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2322 2323 2232 2233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2330 2331 2240 2241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2484 2485 2394 2395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2722 2723 2632 2633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2809 2812 2719 2722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">172</sup>
###xml 2850 2854 2760 2764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 2863 2864 2773 2774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2962 2966 2872 2876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 3126 3127 3032 3033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 3226 3227 3132 3133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 3284 3288 3190 3194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 3390 3391 3263 3264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 3400 3401 3273 3274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3421 3422 3294 3295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
Energy homeostasis in the liver in response to PEPCK-C silencing. A: High-resolution respirometry in isolated hepatocytes from fed mice 14 days after infection with Ad-shCT (blacksquare, square, filled) or Ad-shPck1 (square) was measured in gluconeogenic medium as described in research design and methods. Measurements of the different mitochondrial chain respiratory states were as follows: Routine respiration was measured in the presence of octanoate, followed by the inhibition of ATP synthase with 1 mug/ml oligomycin, and uncoupled respiration was initiated by the addition of 1 mumol/l FCCP followed by 5 mumol/l antimycin A to stop respiration. Finally, cytochrome c oxidase (COX) activity (JCOX) was measured in the presence of 2 mmol/l ascorbate and 500 mumol/l N,N,N',N'-tetramethyl-p-phenylenediamine in each sample. COX activity measurements served as internal measurement normalization. Inset: Respiratory indexes (44) were calculated as follows: RCR, an indicator of the extent of respiration uncoupling, is the quotient between fully uncoupled respiration (FCCP) and the respiration in the presence of oligomycin. UCR, an estimate of the respiratory capacity reserve, is the quotient between fully uncoupled respiration (FCCP) and routine respiration (octanoate). Finally, RCRP, a coefficient indicating the portion of respiratory capacity applied to ATP synthesis, is calculated by subtracting oligomycin respiration from routine respiration and dividing by FCCP respiration. Data are means +/- SE (n = 5). section signP = 0.06, Student's t test. B: Expression of significant genes involved in mitochondrial function (ucp2, cpt1, and hmgc2) was examined in fed Ad-shCT (n = 10; blacksquare, square, filled) or Ad-shPck1 (n = 11; square) animals. Total RNA was extracted with RNAeasy mini kit (Qiagen). cDNA synthesis was performed using Ready-To-Go You-Prime First Strand Beads (Amersham Biosciences) with random hexamers. Gene expression was quantified by quantitative RT-PCR using Applied Biosystems 7900HT Micro Fluidic Card, and data were analyzed using the DeltaDeltaCt method. Gene expression was normalized using beta-2-microglobulin as housekeeping gene. Values represent the mean relative amount of mRNA with respect to that in the control experimental treatment (Ad-shCT). *P < 0.05, Student's t test. C: Mitochondrial inner membrane ADP transporter content VDAC, detected by Western blot, was used as indicator of mitochondrial respiratory chain content. D: Cellular protein content of the cytosolic (SOD-1) and mitochondrial (SOD-2) forms of SOD were used as indicators of cellular oxidative stress after hepatic PEPCK-C silencing as detected by Western blot. Representative blots are shown. E: Western blot analysis of AMPK protein content and phosphorylation levels (AMPK-P Thr172) in fed livers from Ad-shCT and Ad-shPck1 groups. F: Sirt1 protein levels in fed livers form control (Ad-shCT) or PEPCK-C silencing adenovirus (Ad-shPck1) animals were estimated by Western blotting. All blots were normalized using gamma-tubulin. Representative blots from three independent experiments are shown. G: Densitometric quantification of Sirt1 protein content in fed livers performed from blot shown in F confirms a significant reduction of the protein in Ad-shPck1 (square) compared with Ad-shCT (blacksquare, square, filled) treatment group. Data are means +/- SE, n = 6; ***P < 0.001, Student's t test.
###end p 81
###begin p 82
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
Metabolic profile of db/db mice after partial liver silencing of PEPCK-C
###end p 82
###begin p 83
###xml 23 24 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 44 45 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 60 64 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
###xml 67 68 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 91 95 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pck1</italic>
Data are means +/- SE. n = 13-16 (Ad-shCT), n = 15-18 (Ad-shPck1), n = 6 (Ad-shCT and Ad-shPck1).
###end p 83
###begin p 84
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05;
###end p 84
###begin p 85
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
P < 0.01 vs. control virus treatment in fed experiments; unpaired Student's t test.
###end p 85
###begin p 86
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01;
###end p 86
###begin p 87
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 81 82 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
P < 0.001 vs. control virus treatment in fasting experiments; unpaired Student's t test. ND, nondetermined. Sera were obtained 14 days after adenoviral infection from fed or overnight-fasted mice. GPT, glutamic pyruvic transaminase.
###end p 87
###begin p 88
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
Nucleotide and short-chain acyl-CoA content in fed db/db livers
###end p 88
###begin p 89
###xml 23 24 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Data are means +/- SE. n = 8.
###end p 89
###begin p 90
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05;
###end p 90
###begin p 91
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
P < 0.01 vs. control virus treatment; unpaired Student's t test. Tissue was obtained 14 days after treatment. CEC = (ATP + 1/2 AMP)/(ATP + ADP + AMP).
###end p 91

